Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Amiloride

Amiloride
In stock
5mg
from 22,93 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
27,52 £22,93 £
0,23 £ per tablet

In brief

  • Amiloride is a prescription-only medicine (POM) in the UK.
  • Amiloride is used to treat oedema, hypertension and congestive heart failure; it is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the distal tubule and collecting duct, reducing sodium reabsorption and decreasing potassium excretion.
  • The usual adult dose is 5–10 mg once daily as a starting dose; for congestive heart failure 5–20 mg/day in divided doses may be used (do not exceed 20 mg/day); when combined with a thiazide diuretic, amiloride often starts at 5 mg.
  • Administered orally as tablets (5 mg); available alone or in combination products with thiazides.
  • The effect typically begins within about 2 hours after an oral dose, with peak diuretic/natriuretic effect at around 6–10 hours.
  • The duration of action is approximately 24 hours, so once-daily dosing is usual for many indications.
  • Avoid excessive alcohol while taking amiloride — alcohol can worsen dizziness, orthostatic hypotension and dehydration and may exacerbate electrolyte disturbances.
  • The most common side effect is hyperkalaemia (high potassium); other frequent effects include nausea, vomiting, diarrhoea, headache, dizziness, muscle cramps and fatigue; severe hyperkalaemia can cause cardiac arrhythmia.
  • Would you like to try amiloride without a prescription?

Basic amiloride information

  • INN (international nonproprietary name): Amiloride
  • Brand names available in the United Kingdom: Amiloride Hydrochloride — 5 mg tablets; commonly supplied in packs of 28 or 56 tablets by Mylan, Teva and Bristol
  • ATC code: C03DB01
  • Forms and dosages: Tablets 5 mg; combination products with thiazide diuretics (e.g. hydrochlorothiazide/amiloride) are marketed
  • Manufacturers in the United Kingdom: Mylan, Teva, Bristol Labs
  • Registration status in the United Kingdom: Listed with the MHRA as “Amiloride Hydrochloride”; prescription-only medicine
  • OTC / Rx classification: Prescription-only medicine (POM) — prescription required in the UK

Critical warnings and restrictions — patient safety first (UK focus)

Who needs to be extra careful about amiloride?

Patients at high risk include older people, pregnant or breastfeeding women, and people with chronic illnesses such as diabetes or renal disease.

Amiloride is a prescription-only medicine and requires specialist oversight.

Absolute contraindications include anuria, acute or chronic severe renal impairment, Addison’s disease, known hypersensitivity, and baseline hyperkalaemia greater than 5.5 mmol/L.

Elderly people should start low — typically 5 mg — and have serum potassium and renal function monitored more frequently.

Pregnant or breastfeeding patients should avoid amiloride unless the prescriber and obstetrician consider benefits clearly outweigh risks, and informed consent is documented.

People with diabetes or moderate renal impairment need dose adjustments and closer monitoring due to higher hyperkalaemia risk.

High‑risk groups (elderly, pregnancy, chronic illness)

  • Elderly: Start at 5 mg; monitor potassium and eGFR more often than usual.
  • Pregnancy/breastfeeding: Avoid unless essential; discuss with obstetric team and document consent.
  • Renal disease/diabetes: Reduce dose or avoid in moderate-to-severe impairment; monitor electrolytes closely.

Checklist for clinicians before starting amiloride

  • Baseline eGFR and blood urea — record in notes.
  • Baseline serum potassium — do not start if >5.5 mmol/L.
  • Pregnancy status and breastfeeding review.
  • Review concomitant drugs that raise potassium (ACE inhibitors, ARBs, potassium supplements, trimethoprim, NSAIDs, heparin, other potassium‑sparing agents).
  • Set a monitoring schedule: baseline, 1–2 weeks after start or dose change, then monthly/3–6 monthly depending on risk.
  • Document informed consent for higher-risk or off‑label use.

Interaction with activities (driving, workplace safety under UK law)

Dizziness and headache are reported adverse effects with amiloride.

If a patient experiences dizziness, weakness or blurred vision they must not drive or operate heavy machinery until symptoms resolve.

Advise patients that persistent side effects affecting alertness should be reported to the prescriber and may affect fitness to drive under DVLA guidance.

Q&A — “Can I drive after taking it in the UK?”

Q: Can I drive after starting amiloride?

A: If you feel dizzy, weak or have blurred vision, do not drive.

A: Report persistent symptoms to your prescriber and record advice in the patient notes.

A: Check DVLA guidance if side effects affect your fitness to drive.

Usage basics

INN, brand names available in the UK

INN: Amiloride.

In the UK the licensed listing is “Amiloride Hydrochloride” usually as 5 mg tablets supplied by Mylan, Teva and Bristol.

Legal classification (POM, P, GSL)

Amiloride is a prescription-only medicine (POM) in the United Kingdom and requires a valid prescription from an authorised prescriber.

NHS prescriptions can be issued electronically via the Electronic Prescription Service or as private handwritten prescriptions.

Repeat dispensing must be authorised by the prescriber and documented in the patient record.

Patient-facing labelling points

  • Clear dose (eg, 5 mg once daily) and purpose (potassium-sparing diuretic).
  • Monitoring requirements: baseline and follow-up blood tests for potassium and renal function.
  • Keep out of reach of children.
  • Advice on side effects and when to seek urgent help (muscle weakness, palpitations).

Dosing guide

Standard regimens (NHS-style guidance)

Typical adult starting dose is 5–10 mg once daily depending on indication and comorbidity.

For congestive heart failure dosing ranges from 5–20 mg/day in divided doses with a maximum of 20 mg/day.

Standard UK formulation is 5 mg tablets supplied in packs of 28 or 56.

When used with thiazide diuretics, clinicians often start with 5 mg amiloride combined with the thiazide component, as per local formulary combinations.

Recommended dose regimens (patient card format)

Situation Starting dose Titration steps Maximum dose
Oedema / hypertension 5–10 mg once daily Increase by 5 mg after review and labs 20 mg/day
Congestive heart failure 5 mg once daily Increase to 5 mg twice daily then up to 20 mg/day as needed 20 mg/day
With thiazide diuretic 5 mg with thiazide component Titrate thiazide per BP/oedema response; monitor K+ 20 mg/day

Adjustments for comorbidities

  • Renal impairment: Avoid in severe impairment or anuria; use minimal dose and frequent electrolyte checks in mild/moderate disease.
  • Elderly: Start at 5 mg and monitor renal function and potassium closely.
  • Children: Not routinely recommended under 18 years — seek specialist advice.

Q&A — “What if I miss a dose?”

Q: Missed dose?

A: Take the missed dose as soon as you remember unless the next dose is due soon.

A: Do not take a double dose to make up for a missed one.

A: If unsure, contact the pharmacist or prescriber.

A: For suspected overdose with symptoms such as muscle weakness or palpitations, seek urgent medical attention and bring the medication packaging.

Interaction chart

Food and drinks (alcohol, tea/coffee, diet habits)

No major direct food interactions are recorded, but diets high in potassium and use of potassium salt substitutes increase risk of hyperkalaemia.

Recommend consistent potassium intake and avoid sudden large increases in high‑potassium foods without clinical advice.

Alcohol may worsen dizziness and dehydration; counsel moderation.

Common drug conflicts

Key drug interactors that raise hyperkalaemia risk include ACE inhibitors, ARBs, potassium supplements, potassium-sparing diuretics, NSAIDs, trimethoprim and heparin.

Concomitant use with lithium requires monitoring due to potential for altered lithium handling.

Drug class Interaction type Risk level Monitoring required
ACE inhibitors / ARBs Synergistic potassium-raising High Baseline and frequent K+ and eGFR checks
Potassium supplements / salt substitutes Direct potassium increase High Avoid or monitor closely
NSAIDs Reduce renal perfusion, raise K+ Moderate Check renal function and K+ more often
Trimethoprim Blocks renal K+ excretion High Monitor K+ during co-prescribing
Heparin Can increase serum K+ Moderate Monitor electrolytes

Report suspected adverse drug reactions via the MHRA Yellow Card scheme.

How to submit a Yellow Card: visit the MHRA website, complete the online form or use the Yellow Card app to report suspected reactions with details of concomitant medicines and lab results where possible.

Legal status and availability in the UK

In our online pharmacy, amiloride is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Mechanism and pharmacology

Simplified explanation

Amiloride is a potassium‑sparing diuretic that inhibits epithelial sodium channels (ENaC) in the distal nephron.

By blocking ENaC it decreases sodium reabsorption and reduces urinary potassium excretion, which can raise serum potassium.

ATC classification is C03DB01.

Clinical pharmacology terms

  • ENaC: Epithelial sodium channel targeted by amiloride.
  • Hyperkalaemia: Elevated serum potassium that can cause muscle weakness and cardiac arrhythmias.
  • ATC code: C03DB01 — potassium-sparing diuretics, plain.

Onset and duration are consistent with an orally active small-molecule diuretic; accumulation can occur with renal impairment, increasing hyperkalaemia risk.

Indications and off‑label uses

MHRA‑approved uses

Licensed uses in UK practice include use as a potassium‑sparing diuretic adjunct for oedema and hypertension, commonly combined with thiazide diuretics.

Amiloride is nationally listed with MHRA and is prescription-only.

Off‑label practices in NHS and private care

Off‑label uses include selective low-dose use in heart failure to limit hypokalaemia when loop or thiazide diuretics are required.

Off‑label prescribing should be documented with informed consent and include enhanced monitoring such as baseline and early follow-up potassium and eGFR checks.

  • Approved indications: Adjunct potassium-sparing diuretic for oedema and hypertension; combination with thiazides.
  • Common off‑label uses: Low-dose use in heart failure to avoid hypokalaemia; specialist-directed electrolyte-sparing strategies.

Alternatives matrix

NHS prescribing alternatives (comparison table)

Drug Mechanism Potassium effect Typical indications Monitoring intensity
Triamterene ENaC blocker Spares potassium Oedema, adjunct to thiazides Moderate
Spironolactone Aldosterone antagonist Raises potassium Resistant hypertension, heart failure, ascites High
Eplerenone Aldosterone antagonist Raises potassium Heart failure post-MI, hypertension High
Thiazides / loop diuretics Inhibit Na+ transport at different nephron sites Can lower potassium (thiazide) or variable (loop) Hypertension, oedema Variable

Pros and cons checklist

  • If hyperkalaemia risk is unacceptable, prefer thiazide alone or loop diuretic with potassium monitoring.
  • For resistant oedema or ascites, consider spironolactone though it carries similar potassium risks and requires monitoring.
  • Triamterene can be an alternative where amiloride is unsuitable, but it has its own safety profile and monitoring needs.

Common questions (patient FAQs from UK consultations)

  • Will amiloride make my potassium high? Yes; baseline and periodic serum potassium measurements are mandatory; report muscle weakness or palpitations immediately.
  • How often will I need blood tests? Baseline, then within 1–2 weeks after starting or changing dose, then frequency depends on comorbidities — typically monthly until stable, then every 3–6 months.
  • Can I take other medicines? Always check with the prescriber or pharmacist; avoid potassium supplements and inform clinicians about ACE inhibitors, ARBs, NSAIDs and trimethoprim.
  • Can I travel with it? Yes — keep original packaging and a copy of the prescription or repeat slip; store at recommended temperatures and carry contact details for the prescriber.

Registration and regulation

MHRA approval process

Amiloride is approved and listed by the MHRA as “Amiloride Hydrochloride” and is prescription-only.

Up-to-date regulatory details are given in the MHRA product information and SPC.

NHS prescribing framework

Prescribing should follow local primary care formularies and NICE guidance where applicable.

Use repeat prescription templates and monitoring reminders within GP IT systems to flag high-potassium risks.

Report suspected adverse events through the MHRA Yellow Card scheme.

Storage and handling (UK household and pharmacy)

UK household storage (cold/damp climate)

Store at 20–25°C and protect from moisture and light.

Avoid storing in bathrooms where humidity fluctuates and keep in original blister packs or bottles.

Keep out of reach of children and pets; avoid extremes of temperature during travel.

Guidance from NHS and pharmacists

Pharmacists should counsel patients on storage, expiry dates and safe disposal via pharmacy take-back schemes.

Do not flush unused tablets; return them to pharmacy for safe disposal.

Community pharmacy stock should follow manufacturer storage guidance; cold chain is not required but avoid heat.

  • Patient checklist for home storage: store at room temperature, keep in original packaging, check expiry, return unused medicine to pharmacy.

Guidelines for proper use — counselling and safety

UK pharmacist counselling style

Explain why the medicine is prescribed in plain language and how and when to take it.

Highlight side effects to watch for, particularly signs of hyperkalaemia such as muscle weakness or palpitations.

Provide the blood test schedule and review potential interactions, including ACE inhibitors, ARBs, NSAIDs and potassium supplements.

Use the teach-back method by asking the patient to repeat instructions to confirm understanding.

Provide a printed medication card listing dose and monitoring dates.

NHS patient safety advice

Document baseline results in the primary care record and set safety-netting instructions for severe symptoms (severe weakness, palpitations).

Advise escalation pathways including GP, NHS 111 or emergency department if severe signs occur.

Encourage use of NHS apps or repeat prescription services to help patients keep monitoring appointments.

Delivery across the United Kingdom

City Region Delivery Time
London Greater London 9–21 days
Birmingham West Midlands 9–21 days
Manchester Greater Manchester 9–21 days
Glasgow Scotland 9–21 days
Edinburgh Scotland 9–21 days
Bristol South West 9–21 days
Leeds West Yorkshire 9–21 days
Cardiff Wales 9–21 days
Belfast Northern Ireland 9–21 days
Newcastle Upon Tyne North East 9–21 days
Southampton South East 9–21 days
Nottingham East Midlands 9–21 days
Norwich East of England 9–21 days
Exeter South West 9–21 days

Final notes and practical tips

Amiloride is a useful potassium‑sparing diuretic when used carefully and monitored appropriately.

The primary safety concern is hyperkalaemia, especially with renal impairment, diabetes, older age or co-prescribing of potassium‑raising agents.

Keep monitoring simple: baseline blood tests, check at 1–2 weeks after start or dose change, then tailor frequency to risk.

When in doubt, consult the local formulary or specialist and document rationale and monitoring in the clinical record.

For patients, the key messages are clear dosing, when to expect blood tests, signs of high potassium and when to get urgent care.

Related products